-transparent.png){kind=logo}
1 The effects of cholestyramine and nicotinic acid on plasma lipid concentration have been compared in patients with type IIa hyperlipoproteinaemia. 2 During a 3-month period, cholestyramine resulted in a mean decrease in cholesterol levels of 26%. Triglyceride levels rose in eight of the ten patients during treatment with this drug but in the majority of patients remained within the normal range. 3 During nicotinic acid therapy, cholesterol fell by a mean of 21% and triglyceride by a mean of 23%. 4 The slow release preparation of nicotinic acid used was acceptable to the majority of the patients studied and the results therefore suggest that this drug may be a useful alternative to the more widely used agent, cholestyramine.
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1973,
The Netherlands journal of medicine,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
June 1981,
Lancet (London, England),
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1982,
Artery,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1975,
Postgraduate medical journal,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1975,
Postgraduate medical journal,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
December 1973,
Casopis lekaru ceskych,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1976,
Acta medica Scandinavica,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1971,
Atherosclerosis,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
May 1973,
The Medical journal of Australia,
J I Mann, and
P A Harding, and
R C Turner, and
R H Wilkinson
January 1973,
Lancet (London, England),
